As Canberra's famous LGBTQI+ Qwire gears up for its 30th anniversary birthday concert "Singing Out with Pride," conductor Lachlan Snow is busy putting the choristers through their paces.
Dosed first patient in the global Phase 2 study of NTLA-2002 for the treatment of hereditary angioedema (HAE)Expects to complete enrollment in the Phase 2 study of NTLA-2002 in 2H 2023Plans to submit IND
CAMBRIDGE, Mass., March 21, 2023 Intellia Therapeutics, Inc. , a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based. | March 21, 2023
Intellia Therapeutics Awarded Innovation Passport in the United Kingdom for NTLA-2002, an Investigational Genome Editing Treatment for Hereditary Angioedema - read this article along with other careers information, tips and advice on BioSpace